{"filing":{"accession_number":"0001493152-26-035323","cik":"0001938046","ticker":"MGRX","company_name":"MANGOCEUTICALS, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-28","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/form8-k.htm"},"events":[{"id":22016,"run_id":19884,"accession_number":"0001493152-26-035323","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses entry into a definitive Business Combination Agreement (BCA) between Mangoceuticals and Nuclea Energy Inc., whereby a newly formed subsidiary of Mangoceuticals will amalgamate with Nuclea. Nuclea shareholders will receive exchangeable shares convertible into Mangoceuticals common stock on a one-for-one basis, resulting in former Nuclea shareholders holding approximately 96% of Mangoceuticals' equity post-transaction. This is a material acquisition/change of control transaction requiring stockholder approval and Nasdaq listing approval, with closing expected prior to receipt of Required Approvals and a $15 million minimum PIPE financing condition.","company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":21821,"accession_number":"0001493152-26-035323","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a definitive Business Combination Agreement (BCA) between Mangoceuticals and Nuclea Energy Inc., whereby a newly formed subsidiary of Mangoceuticals will amalgamate with Nuclea. Nuclea shareholders will receive exchangeable shares convertible into Mangoceuticals common stock on a one-for-one basis, resulting in former Nuclea shareholders holding approximately 96% of Mangoceuticals' equity post-transaction. This is a material acquisition/change of control transaction requiring stockholder approval and Nasdaq listing approval, with closing expected prior to receipt of Required Approvals and a $15 million minimum PIPE financing condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:03:05.556898+00:00","company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","filing_date":"2026-07-30"}]}